"Use of GLP-1 [drugs] is rapidly expanding in this population, highlighting an important area for future research." More information The Mayo Clinic has more on GERD
The broader GLP-1 class also remains under active legal scrutiny: more than 4,400 lawsuits have been filed against Eli Lilly and Novo Nordisk in multidistrict litigation alleging failure to warn about gastroparesis and vision loss linked to existing semaglutide and tirzepatide products, though neither orforglipron nor retatrutide is named in that litigation
General Safety & Handling Not for Human Use These compounds are for research only
Verify 2 - Billing cycle start date
Any shift in how you relate to food tends to follow from those changes, not from the peptide directly
Indeed, we reported recently that whereas glucagon per se failed to augment FOC in HAP, in the presence of elevated cAMP (cilostamide added), glucagon increased FOC (Neumann et al